Cancer Research

Joe Biden’s longtime ties to Penn

As the nation prepares for its 46th president to take office Wednesday, Jan. 20, Penn Today reflects on the lasting impact he’s had at the University.

Lauren Hertzler

The backlog in mammograms during the COVID-19 pandemic

The backlog of diagnostic mammograms is not expected to return to regular operations for nearly six months at best, and a lack of early detection will have health implications on cancer management for years to come.

From Penn LDI

Priming the immune system to attack cancer

An international team, co-led by the School of Dental Medicine’s George Hajishengallis, showed how immune “training” transforms certain immune cells to target tumors.

Katherine Unger Baillie



In the News


Forbes

Carl June: 2024 will be seen as a breakthrough year for brain cancer

Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.

FULL STORY →



Philadelphia Inquirer

Penn plans to build a proton center for cancer treatment at Presbyterian Medical Center

Penn Medicine will build its fourth proton beam center for cancer treatment at Penn Presbyterian Medical Center in University City.

FULL STORY →



PhillyVoice

Double mastectomies do not improve breast cancer survival likelihood for most women, study finds

Angela DeMichele of the Perelman School of Medicine says that chemotherapy and hormonal therapies are important for combating breast cancer because they’re designed to kill spreading cells.

FULL STORY →



The New York Times

Breast cancer survival not boosted by double mastectomy, study says

Angela DeMichele of the Perelman School of Medicine comments on a study which found that breast cancer survival is not boosted by a double mastectomy.

FULL STORY →



Today

How did Shannen Doherty die? What to know about ‘90210’ star’s cause of death

According to Penn Medicine, there is no known cure for metastatic breast cancer.

FULL STORY →



Stat

New immunotherapy combination could ‘change the landscape’ of cancer treatment

A study by Andy Minn and postdoc Divij Mathew of the Perelman School of Medicine and colleagues found that a combination checkpoint inhibitor therapy benefited patients with lung cancer.

FULL STORY →